search
Back to results

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

Primary Purpose

Oral Submucous Fibrosis

Status
Completed
Phase
Phase 3
Locations
Pakistan
Study Type
Interventional
Intervention
Nigella sativa oil
Betamethasone Valerate
Sponsored by
Ziauddin University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Oral Submucous Fibrosis focused on measuring OSMF

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with the age of 18 years and above
  • Patients clinically diagnosed with Oral submucous fibrosis
  • Patients who have not received any treatment for Oral submucous fibrosis in the last three months.
  • Patients who are willing to quit the habit of eating pan, gutka and areca nut
  • Patients who are willing to attend the follow up visits

Exclusion Criteria:

  • Patients who are less than 18 years of age
  • Patients who are already using pain medications, corticosteroids or immunosuppressive drugs in any other form
  • Patients with a history of malignancy
  • Patients presenting with oral lesions other than Oral submucous fibrosis (OSMF)
  • Patients who are allergic to the drug material used in the clinical trial
  • Patients who will not give consent

Sites / Locations

  • Ziauddin University, Clifton

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Steroid group

Nigella Sativa oil group

Arm Description

Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).

Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).

Outcomes

Primary Outcome Measures

Pain assessed using visual analogue scale (VAS)
Pain will be measured using VAS. This scale usually present as a 100-mm horizontal line on which the pain intensity experienced by the patient will be represented by a point between the extremes of "no pain at all" and "worst pain imaginable.
Inter-incisal mouth opening (IMO) assessed using vernier caliper
Interincisal mouth opening will be calculated by measuring the distance between the mesioincisal angles of the maxillary central incisor and the mandibular central incisor with the help of a vernier calliper.

Secondary Outcome Measures

Cheek Flexibility assessed following the method of Mathur and Jha (1993)
A line will be drawn from the tragus of the ear to the angle of the mouth and then two reference points will be marked on both the cheeks at 1/3rd the distance from the angle of the mouth on the line drawn previously. After marking these reference points, the patient will be asked to blow his cheek and the distance will be measured between the two points. Then the patient will be instructed to relax his cheeks and the distance will be measured again. The difference between the two values will give the value for cheek flexibility.
Tongue protrusion
Tongue protrusion will be recorded by measuring the distance between the tip of the tongue and the mesioincisal angle of the upper central incisor using steel ruler.

Full Information

First Posted
July 2, 2020
Last Updated
March 14, 2022
Sponsor
Ziauddin University
search

1. Study Identification

Unique Protocol Identification Number
NCT04476420
Brief Title
Comparative Effect of Nigella Sativa and Conventional Management for OSMF
Official Title
Comparison of Nigella Sativa Oil With Conventional Management on Clinical Outcomes in Oral Submucous Fibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
February 11, 2021 (Actual)
Primary Completion Date
September 30, 2021 (Actual)
Study Completion Date
September 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ziauddin University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Oral submucous fibrosis (OSMF) is a potentially malignant condition mainly characterized by inflammation and fibrosis of the submucosal tissues leading to marked rigidity and reduced opening of the jaws. OSMF has a multifactorial etiology but areca nut consumption is considered to be the most consistent factor in its pathogenesis. There is no definitive treatment available for treating OSMF. Conventional management involves physiotherapy exercises and treating the disease with certain medications such as steroids and homeopathic medications.
Detailed Description
OSMF is a chronic insidious disorder of the oral cavity which has a great potential to turn malignant. The clinical manifestations of OSMF comprise of white, marble-like appearance of the oral mucosa with loss of flexibility and formation of palpable fibrous bands extending from the anterior to the posterior region of the oral cavity.Other features include burning sensation on taking spicy food, loss of papillae of the tongue, loss of natural pigmentation of the lips and restricted mouth opening. There is no definitive treatment available for OSMF due to its complex etiology. The most essential component in the management of OSMF is the discontinuation of the habit of areca nut chewing by the patient followed by conservative or surgical treatment. Currently, steroids are the most commonly used drug group in managing OSMF because of their ability to reduce the inflammatory process and increasing the apoptosis of inflammatory cells thereby decreasing fibrosis. However, they are not very useful in reversing the pathology and restoring mucosal elasticity and can cause mucosal thinning with long term use ultimately resulting in worsening of the symptoms of the disease. Many in- vitro and in- vivo studies have been conducted to establish the anti neoplastic, anti inflammatory, immunomodulatory, antihypertensive, antimicrobial, anti-parasitic, antioxidant and hypoglycemic properties of N.sativa oil. Among all the constituents of Nigella sativa, Thymoquinone (Tq) is the most pharmacologically active constituent responsible for most of its properties. Nigella sativa has been used widely in different food preparations in the form of a flavoring agent or a spice. It is also recognized as 'safe' in the inventory of United States Food and Drug administration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oral Submucous Fibrosis
Keywords
OSMF

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
39 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Steroid group
Arm Type
Active Comparator
Arm Description
Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
Arm Title
Nigella Sativa oil group
Arm Type
Experimental
Arm Description
Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
Intervention Type
Dietary Supplement
Intervention Name(s)
Nigella sativa oil
Intervention Description
Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
Intervention Type
Drug
Intervention Name(s)
Betamethasone Valerate
Other Intervention Name(s)
Corticosteroid
Intervention Description
it is a conventionally used drug for treating OSMF
Primary Outcome Measure Information:
Title
Pain assessed using visual analogue scale (VAS)
Description
Pain will be measured using VAS. This scale usually present as a 100-mm horizontal line on which the pain intensity experienced by the patient will be represented by a point between the extremes of "no pain at all" and "worst pain imaginable.
Time Frame
6 months
Title
Inter-incisal mouth opening (IMO) assessed using vernier caliper
Description
Interincisal mouth opening will be calculated by measuring the distance between the mesioincisal angles of the maxillary central incisor and the mandibular central incisor with the help of a vernier calliper.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Cheek Flexibility assessed following the method of Mathur and Jha (1993)
Description
A line will be drawn from the tragus of the ear to the angle of the mouth and then two reference points will be marked on both the cheeks at 1/3rd the distance from the angle of the mouth on the line drawn previously. After marking these reference points, the patient will be asked to blow his cheek and the distance will be measured between the two points. Then the patient will be instructed to relax his cheeks and the distance will be measured again. The difference between the two values will give the value for cheek flexibility.
Time Frame
6 months
Title
Tongue protrusion
Description
Tongue protrusion will be recorded by measuring the distance between the tip of the tongue and the mesioincisal angle of the upper central incisor using steel ruler.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with the age of 18 years and above Patients clinically diagnosed with Oral submucous fibrosis Patients who have not received any treatment for Oral submucous fibrosis in the last three months. Patients who are willing to quit the habit of eating pan, gutka and areca nut Patients who are willing to attend the follow up visits Exclusion Criteria: Patients who are less than 18 years of age Patients who are already using pain medications, corticosteroids or immunosuppressive drugs in any other form Patients with a history of malignancy Patients presenting with oral lesions other than Oral submucous fibrosis (OSMF) Patients who are allergic to the drug material used in the clinical trial Patients who will not give consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hira Batool, Mphil
Organizational Affiliation
Ziauddin University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ziauddin University, Clifton
City
Karachi
State/Province
Sindh
ZIP/Postal Code
75600
Country
Pakistan

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

We'll reach out to this number within 24 hrs